| Deborah Schoenlein Smith, RN MS CNS | |
|
900 Veterans Blvd, Suite 300, Redwood City, CA 94063-1715 | |
| (650) 299-4959 | |
| Not Available |
| Full Name | Deborah Schoenlein Smith |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 900 Veterans Blvd, Redwood City, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386807063 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 2560 (California) | Primary |
| 163W00000X | Registered Nurse | 377849 (California) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Deborah Schoenlein Smith, RN MS CNS 2843 Sycamore Way, Santa Clara, CA 95051-5641 Ph: () - | Deborah Schoenlein Smith, RN MS CNS 900 Veterans Blvd, Suite 300, Redwood City, CA 94063-1715 Ph: (650) 299-4959 |
News Archive
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for albuterol sulfate inhalation solution in the 0.021% (base) and 0.042% (base) strengths.
Front-line physicians are advised to err on the side of caution and opt for additional imaging and second opinions when diagnosing six common foot and ankle injuries.
Researchers at Duke University Medical Center and at the National Institute of Environmental Health Sciences (NIEHS) have shown how broken sections of chromosomes can recombine to change genomes and spawn new species.
A new era of manufacturing is upon us. Recent developments in 3D printing and additive manufacturing technologies are set to usher in the next generation of industrial competitiveness.
IDM Pharma, Inc. today announced follow-up results from the Phase 2 study of IDM-2101 showing that the product candidate was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) who were treated with IDM-2101, compared to a parallel external control group of HLA-A2 negative non-treated patients.
› Verified 4 days ago
Carolyn Benson Leonard, RN, MSN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1150 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-3200 | |
Christa Perryman, AGCNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1100 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-7687 | |
Karen Sheng, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 901 Marshall St, Redwood City, CA 94063 Phone: 650-299-3536 | |
Lisa Marie Morse, AGCNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1100 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-2000 | |
Reyzel Rozario, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1100 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-3177 |